West Nile viral infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, this new approach results in rapid virus inactivation while greatly improving the maintenance of WNV-specific neutralizing epitopes mapped across the three structural domains of the WNV envelope protein.
|
30606462 |
2019 |
West Nile viral infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
N-linked glycosylation of the West Nile virus envelope protein is not a requisite for avian virulence or vector competence.
|
31306420 |
2019 |
West Nile viral infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
A common conserved peptide harboring predicted T and B cell epitopes in domain III of envelope protein of Japanese Encephalitis Virus and West Nile Virus for potential use in epitope based vaccines.
|
31300121 |
2019 |
West Nile viral infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
A one-step single tube accelerated quantitative RT-LAMP assay was evaluated by targeting the Env gene of WNV.
|
29923519 |
2018 |
West Nile viral infection
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This sequence of conformational events is similar to those shown to describe fusion by influenza virus hemagglutinin (a "class I" fusogen) and West Nile virus envelope protein ("class II").
|
27974607 |
2017 |
West Nile viral infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
The envelope protein is the main component of the WNV virion surface, and domain III of the envelope protein (EIII) is both a putative receptor binding domain and a target of highly specific, potently neutralizing antibodies.
|
27284640 |
2016 |
West Nile viral infection
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The gene coding for the envelope protein of WNV was cloned and expressed in pET 28a vector followed by purification of recombinant protein by affinity chromatography.
|
23357292 |
2013 |
West Nile viral infection
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
West Nile virus genome with glycosylated envelope protein and deletion of alpha helices 1, 2, and 4 in the capsid protein is noninfectious and efficiently secretes subviral particles.
|
24049184 |
2013 |
West Nile viral infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD4 T cells from WNV vaccinated mice could be stimulated from epitopic regions in the envelope protein transmembrane domain.
|
22244913 |
2012 |
West Nile viral infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
A DNA plasmid was constructed encoding an SCT incorporating the human MHC class I molecule HLA-A2 and the immunodominant peptide SVG9 derived from the envelope protein of West Nile virus (WNV).
|
20212098 |
2010 |
West Nile viral infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells.
|
18996430 |
2009 |
West Nile viral infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
A murine brain cDNA phage display library was therefore probed with WNV envelope protein, resulting in the identification of several adherent peptides.
|
17151121 |
2007 |
West Nile viral infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains.
|
15956579 |
2005 |
West Nile viral infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
Binding assays using yeast surface display demonstrated that all of our scFvs bind to sites within domains I and II of West Nile virus envelope protein.
|
16282460 |
2005 |
West Nile viral infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
The vaccine candidates are chimeric viruses (designated WN/DEN4) bearing the membrane precursor and envelope protein genes of WN on a backbone of dengue 4 virus (DEN4) with or without a deletion of 30 nucleotides (Delta 30) in the 3' noncoding region of DEN4.
|
14517072 |
2003 |